cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity
Open accessAbstract
Conventional type 1 dendritic cells (cDC1)1 are thought to perform antigen cross-presentation, which is required to prime CD8+ T cells 2,3, whereas cDC2 are specialized for priming CD4+ T cells 4,5. CD4+ T cells are also considered to help CD8+ T cell responses through a variety of mechanisms 6-11, including a process whereby CD4+ T cells 'license' cDC1 for CD8+ T cell priming 12. However, this model has not been directly tested in vivo or in the setting of help-dependent tumour rejection. Here we generated an Xcr1 Cre mouse strain to evaluate the cellular interactions that mediate tumour rejection in a model requiring CD4+ and CD8+ T cells. As expected, tumour rejection required cDC1 and CD8+ T cell priming required the expression of major histocompatibility class I molecules by cDC1. Unexpectedly, early priming of CD4+ T cells against tumour-derived antigens also required cDC1, and this was not simply because they transport antigens to lymph nodes for processing by cDC2, as selective deletion of major histocompatibility class II molecules in cDC1 also prevented early CD4+ T cell priming. Furthermore, deletion of either major histocompatibility class II or CD40 in cDC1 impaired tumour rejection, consistent with a role for cognate CD4+ T cell interactions and CD40 signalling in cDC1 licensing. Finally, CD40 signalling in cDC1 was critical not only for CD8+ T cell priming, but also for initial CD4+ T cell activation. Thus, in the setting of tumour-derived antigens, cDC1 function as an autonomous platform capable of antigen processing and priming for both CD4+ and CD8+ T cells and of the direct orchestration of their cross-talk that is required for optimal anti-tumour immunity.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
cDC1 are critical for antigen cross-presentation required to prime CD8+ T cells for optimal anti-tumor immunity and priming of CD4+ T cells at early stages, partly because cDC1 provides antigen transportation to lymph nodes for processing by cDC2.
“cDC1 are critical for antigen cross-presentation required to prime CD8+ T cells for optimal anti-tumor immunity and priming of CD4+ T cells at early stages, partly because cDC1 provides antigen transportation to lymph nodes for processing by cDC2 (36).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [36]
Split into 2 atoms — 0 confirmed, 1 partially supported, 1 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredCD40 signaling in cDC1 is required for tumor rejection by playing a key role in augmenting the proliferation of antigen-specific CD8+ T cells.
“CD40 signaling in cDC1 is required for tumor rejection by playing a key role in augmenting the proliferation of antigen-specific CD8+ T cells (36).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [36]
In the section “CD40 signaling in cDC1 is required for optimal activation of both CD8 and CD4 T cells” (page not provided), mice lacking CD40 on cDC1 failed to reject tumours and showed reduced expansion of antigen-specific CD8 T cells. The paper reports reduced CD8 T-cell proliferation after immunization with cell-associated antigen, but not in tumour-bearing mice; it therefore describes the tumour effect as enhanced expansion and/or persistence, rather than specifically enhanced proliferation. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus
Srinivas, S., Watanabe, T., Lin, C.-S., William, C. M., Tanabe, Y., Jessell, T. M., & Costantini, F. (2001) · BMC Developmental Biology · doi:10.1186/1471-213x-1-4 · Cited by 3,121 · see citing works
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615 · see citing works
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
Ridge, J. P., Rosa, F. D., & Matzinger, P. (1998) · Nature · doi:10.1038/30989 · Cited by 2,360 · see citing works
Help for cytotoxic-T-cell responses is mediated by CD40 signalling
Bennett, S. R. M., Carbone, F., Karamalis, F., Flavell, R. A., Miller, J. F. A. P., & Heath, W. R. (1998) · Nature · doi:10.1038/30996 · Cited by 2,091 · see citing works
Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081 · see citing works
Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny
Guilliams, M., Ginhoux, F., Jakubzick, C., Naik, S. H., Onai, N., Schraml, B. U., Segura, É., Tussiwand, R., & Yona, S. (2014) · Nature reviews. Immunology · doi:10.1038/nri3712 · Cited by 1,802 · see citing works
CD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585 · see citing works
Differential Antigen Processing by Dendritic Cell Subsets in Vivo
Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C., Liu, K., Lee, H., Park, C. G., et al. (2007) · Science · doi:10.1126/science.1136080 · Cited by 1,454 · see citing works
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,285 · see citing works
Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help
Sun, J. C., & Bevan, M. J. (2003) · Science · doi:10.1126/science.1083317 · Cited by 1,213 · see citing works
MHC-II neoantigens shape tumour immunity and response to immunotherapy
Alspach, E., Lussier, D. M., Miceli, A. P., Kizhvatov, I., DuPage, M., Luoma, A. M., Meng, W., Lichti, C. F., Esaulova, E., Vomund, A. N., et al. (2019) · Nature · doi:10.1038/s41586-019-1671-8 · Cited by 846 · see citing works
Schlitzer, A., McGovern, N. N., Teo, P., Zelante, T., Atarashi, K., Low, D., Ho, A. W. S., See, P., Shin, A., Wasan, P. S., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.04.011 · Cited by 834 · see citing works
Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells
Williams, M. A., Tyznik, A. J., & Bevan, M. J. (2006) · Nature · doi:10.1038/nature04790 · Cited by 792 · see citing works
Bennett, S. R. M., Carbone, F., Karamalis, F., Miller, J. F. A. P., & Heath, W. R. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.1.65 · Cited by 725 · see citing works
The multifaceted role of CD4+ T cells in CD8+ T cell memory
Laidlaw, B. J., Craft, J. E., & Kaech, S. M. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.10 · Cited by 657 · see citing works
Sun, J. C.-Y., Williams, M. A., & Bevan, M. J. (2004) · Nature Immunology · doi:10.1038/ni1105 · Cited by 644 · see citing works
A Role for CD40 Expression on CD8 + T Cells in the Generation of CD8 + T Cell Memory
Bourgeois, C., Rocha, B., & Tanchot, C. (2002) · Science · doi:10.1126/science.1072615 · Cited by 641 · see citing works
Šedý, J. R., Gavrieli, M., Potter, K. G., Hurchla, M. A., Lindsley, R. C., Hildner, K. M., Scheu, S., Pfeffer, K., Ware, C. F., Murphy, T. L., et al. (2004) · Nature Immunology · doi:10.1038/ni1144 · Cited by 633 · see citing works
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity
Binnewies, M., Mujal, A. M., Pollack, J. L., Combes, A. J., Hardison, E. A., Barry, K. C., Tsui, J. L., Ruhland, M. K., Kersten, K., Abushawish, M., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.005 · Cited by 629 · see citing works
Satpathy, A. T., Wumesh, K. C., Albring, J. C., Edelson, B. T., Kretzer, N. M., Bhattacharya, D., Murphy, T. L., & MURPHY, K. M. M. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20120030 · Cited by 628 · see citing works
CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death
Janssen, E. M., Droin, N. M., Lemmens, E. E., Pinkoski, M. J., Bensinger, S. J., Ehst, B. D., Griffith, T. S., Green, D. R., & Schoenberger, S. P. (2005) · Nature · doi:10.1038/nature03337 · Cited by 619 · see citing works
Role for Spi-C in the development of red pulp macrophages and splenic iron homeostasis
Kohyama, M., Ise, W., Edelson, B. T., Wilker, P. R., Hildner, K., Mejia, C., Frazier, W. A., Murphy, T. L., & Murphy, K. M. (2009) · Nature · doi:10.1038/nature07472 · Cited by 479 · see citing works
Cognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunity
Smith, C. M., Wilson, N. S., Waithman, J., Villadangos, J. A., Carbone, F. R., Heath, W. R., & Belz, G. T. (2004) · Nature Immunology · doi:10.1038/ni1129 · Cited by 448 · see citing works
Bos, R., & Sherman, L. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1322 · Cited by 445 · see citing works
Ahrends, T., Spanjaard, A., Pilzecker, B., Bąbała, N., Bovens, A. A., Xiao, Y., Jacobs, H., & Borst, J. G. (2017) · Immunity · doi:10.1016/j.immuni.2017.10.009 · Cited by 406 · see citing works
Transcription factor IRF4 drives dendritic cells to promote Th2 differentiation
Williams, J. W., Tjota, M. Y., Clay, B. S., Lugt, B. V., Bandukwala, H. S., Hrusch, C. L., Decker, D. C., Blaine, K. M., Fixsen, B. R., Singh, H., et al. (2013) · Nature Communications · doi:10.1038/ncomms3990 · Cited by 402 · see citing works
Pinschewer, D. D., Ochsenbein, A. F., Odermatt, B., Brinkmann, V., Hengartner, H., & Zinkernagel, R. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.11.5761 · Cited by 365 · see citing works
Design and use of conditional MHC class I ligands
Toebes, M., Coccoris, M., Bins, A. D., Rodenko, B., Gomez, R., Nieuwkoop, N. J., van de Kasteele, W., Rimmelzwaan, G. F., Haanen, J. B. A. G., Ovaa, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1360 · Cited by 348 · see citing works
The Dendritic Cell Receptor Clec9A Binds Damaged Cells via Exposed Actin Filaments
Zhang, J., Czabotar, P. E., Policheni, A. N., Caminschi, I., Wan, S. S., Kitsoulis, S., Tullett, K. M., Robin, A. Y., Brammananth, R., van Delft, M. F., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.009 · Cited by 342 · see citing works
WDFY4 is required for cross-presentation in response to viral and tumor antigens
Theisen, D. J., Davidson, J. T., Briseño, C. G., Gargaro, M., Lauron, E. J., Wang, Q., Desai, P., Durai, V., Bagadia, P., Brickner, J. R., et al. (2018) · Science · doi:10.1126/science.aat5030 · Cited by 341 · see citing works
Robust Anti-Viral Immunity Requires Multiple Distinct T Cell-Dendritic Cell Interactions
Eickhoff, S., Brewitz, A., Gerner, M. Y., Klauschen, F., Komander, K., Hemmi, H., Garbi, N., Kaisho, T., Germain, R. N., & Kastenmüller, W. (2015) · Cell · doi:10.1016/j.cell.2015.08.004 · Cited by 337 · see citing works
Huysamen, C., Willment, J. A., Dennehy, K. M., & Brown, G. D. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709923200 · Cited by 318 · see citing works
Hor, J. L., Whitney, P. G., Zaid, A., Brööks, A. G., Heath, W. R., & Mueller, S. N. (2015) · Immunity · doi:10.1016/j.immuni.2015.07.020 · Cited by 282 · see citing works
Monitoring T cell–dendritic cell interactions in vivo by intercellular enzymatic labelling
Pasqual, G., Chudnovskiy, A., Tas, J. M. J., Agudelo, M., Schweitzer, L. D., Cui, A., Hacohen, N., & Victora, G. D. (2018) · Nature · doi:10.1038/nature25442 · Cited by 266 · see citing works
Ardouin, L., Luche, H., Chelbi, R., Carpentier, S., Shawket, A., Montañana-Sanchis, F., Maria, C. S., Grenot, P., Alexandre, Y. O., Grégoire, C., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.019 · Cited by 228 · see citing works
Kamphorst, A. O., Guermonprez, P., Dudziak, D., & Nussenzweig, M. C. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001205 · Cited by 208 · see citing works
Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel, J.-C., Crozat, K., Dalod, M., & Mattiuz, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00009 · Cited by 190 · see citing works
Cryptic activation of an Irf8 enhancer governs cDC1 fate specification
Durai, V., Bagadia, P., Granja, J. M., Satpathy, A. T., Kulkarni, D. H., Davidson, J. T., Wu, R., Patel, S. J., Iwata, A., Liu, T., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0450-x · Cited by 173 · see citing works
IRF4 Promotes Cutaneous Dendritic Cell Migration to Lymph Nodes during Homeostasis and Inflammation
Bajaña, S., Roach, K., Turner, S., Paul, J. A., & Kovats, S. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102613 · Cited by 171 · see citing works
Ferris, S. T., Carrero, J. A., Mohan, J. F., Calderon, B., Murphy, K. M., & Unanue, E. R. (2014) · Immunity · doi:10.1016/j.immuni.2014.09.012 · Cited by 164 · see citing works
Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers
Andersen, R. S., Kvistborg, P., Frøsig, T. M., Pedersen, N. W., Lyngaa, R., Bakker, A., Shu, C. J., Straten, P. T., Schumacher, T. N., & Hadrup, S. R. (2012) · Nature Protocols · doi:10.1038/nprot.2012.037 · Cited by 132 · see citing works
Virus Subversion of the MHC Class I Peptide-Loading Complex
Lybarger, L. P., Wang, X., Harris, M. R., Virgin, H. W., & Hansen, T. H. (2003) · Immunity · doi:10.1016/s1074-7613(02)00509-5 · Cited by 127 · see citing works
Wu, X., Briseño, C. G., Durai, V., Albring, J. C., Haldar, M., Bagadia, P., Kim, K.-W., Randolph, G. J., Murphy, T. L., & MURPHY, K. M. M. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20160600 · Cited by 116 · see citing works
Naive CD4 T cells constitutively express CD40L and augment autoreactive B cell survival
Lesley, R., Kelly, L. M., Xu, Y., & Cyster, J. G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601539103 · Cited by 92 · see citing works
A conditional null allele of the major histocompatibility IA‐beta chain gene
Hashimoto, K., Joshi, S. K., & Koni, P. A. (2002) · genesis · doi:10.1002/gene.10056 · Cited by 87 · see citing works
Inducible down-regulation of MHC class I results in natural killer cell tolerance
Bern, M. D., Parikh, B. A., Yang, L., Beckman, D. L., Poursine‐Laurent, J., & Yokoyama, W. M. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20181076 · Cited by 78 · see citing works
DC subset–specific induction of T cell responses upon antigen uptake via Fcγ receptors in vivo
Lehmann, C. H. K., Barańska, A., Heidkamp, G. F., Heger, L., Neubert, K., Lühr, J. J., Hoffmann, A., Reimer, K. C., Brückner, C., Beck, S., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20160951 · Cited by 77 · see citing works
Theisen, D. J., Ferris, S. T., Briseño, C. G., Kretzer, N., Iwata, A., Murphy, K. M., & Murphy, T. L. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0138 · Cited by 66 · see citing works
Valdez, Y., Mah, W., Winslow, M. M., Xu, L., Ling, P., & Townsend, S. E. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20010898 · Cited by 63 · see citing works
Archambault, A. S., Carrero, J. A., Barnett, L. G., McGee, N. G., Sim, J. E., Wright, J. O., Raabe, T. D., Chen, P., Ding, H., Allenspach, E. J., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201598 · Cited by 39 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,528 · see citing works
Zhang, Y., Chen, H., Mo, H., Hu, X., Gao, R., Zhao, Y., Liu, B., Niu, L., Sun, X., Yu, X., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.010 · Cited by 783 · see citing works
Cabeza-Cabrerizo, M., Cardoso, A., Minutti, C. M., Pereira da Costa, M., & Reis e Sousa, C. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-061020-053707 · Cited by 757 · see citing works
Dendritic cell subsets in cancer immunity and tumor antigen sensing
Prete, A. D., Salvi, V., Soriani, A., Laffranchi, M., Sozio, F., Bosisio, D., & Sozzani, S. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-00990-6 · Cited by 663 · see citing works
Speiser, D. E., Chijioke, O., Schaeuble, K., & Münz, C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00521-2 · Cited by 486 · see citing works
Cui, C., Wang, J., Fagerberg, E., Chen, P.-M., Connolly, K. A., Damo, M., Cheung, J. F., Mao, T., Askari, A. S., Chen, S., et al. (2020) · Cell · doi:10.1016/j.cell.2021.11.007 · Cited by 475 · see citing works
CD8+ T cells in the cancer-immunity cycle
Giles, J. R., Globig, A.-M., Kaech, S. M., & Wherry, E. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.005 · Cited by 473 · see citing works
Magen, A., Hamon, P., Fiaschi, N., Soong, B. Y., Park, M. D., Mattiuz, R., Humblin, E., Troncoso, L., D’souza, D., Dawson, T., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02345-0 · Cited by 429 · see citing works
Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer
Huang, L., Rong, Y., Tang, X., Yi, K., Qi, P., Hou, J., Liu, W., He, Y. Z., Gao, X., Yuan, C., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01515-x · Cited by 413 · see citing works
Dendritic cells as orchestrators of anticancer immunity and immunotherapy
Heras‐Murillo, I., Adán‐Barrientos, I., Galán, M. Á., Wculek, S. K., & Sancho, D. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00859-1 · Cited by 403 · see citing works
Cancer vaccines: Building a bridge over troubled waters
Sellars, M., Wu, C. J., & Fritsch, E. F. (2022) · Cell · doi:10.1016/j.cell.2022.06.035 · Cited by 322 · see citing works
Dendritic cells as shepherds of T cell immunity in cancer
Pittet, M. J., Pilato, M. D., Garris, C., & Mempel, T. R. (2023) · Immunity · doi:10.1016/j.immuni.2023.08.014 · Cited by 326 · see citing works
Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy
Basu, A. B., Ramamoorthi, G., Albert, G. K., Gallen, C., Beyer, A., Snyder, C., Koski, G. K., Disis, M. L., Czerniecki, B. J., & Kodumudi, K. N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669474 · Cited by 318 · see citing works
CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours
Kruse, B., Buzzai, A. C., Shridhar, N., Braun, A. D., Gellert, S., Knauth, K., Poźniak, J., Peters, J., Dittmann, P., Mengoni, M., et al. (2023) · Nature · doi:10.1038/s41586-023-06199-x · Cited by 326 · see citing works
SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity
Guo, C., You, Z., Shi, H., Sun, Y., Du, X.-R., Palacios, G., Guy, C., Yuan, S.-J., Chapman, N. M., Lim, S., et al. (2023) · Nature · doi:10.1038/s41586-023-06299-8 · Cited by 307 · see citing works
The role of dendritic cells in cancer and anti-tumor immunity
Marciscano, A. E. E., & Anandasabapathy, N. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101481 · Cited by 305 · see citing works
Cancer immune evasion, immunoediting and intratumour heterogeneity
Roerden, M., & Spranger, S. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-024-01111-8 · Cited by 286 · see citing works
Dendritic cells in cancer immunology
Murphy, T. L., & MURPHY, K. M. M. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00741-5 · Cited by 272 · see citing works
Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
Pei, L., Liu, Y., Liu, L., Gao, S., Gao, X., Feng, Y., Sun, Z., Zhang, Y., & Wang, C. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01731-z · Cited by 265 · see citing works
Human dendritic cells in cancer
Kvedaraite, E., & Ginhoux, F. (2022) · Science Immunology · doi:10.1126/sciimmunol.abm9409 · Cited by 261 · see citing works
Abdominal Aortic Aneurysm: Roles of Inflammatory Cells
Yuan, Z., Lü, Y., Wei, J., Wu, J., Yang, J., & Cai, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.609161 · Cited by 232 · see citing works
Exploiting innate immunity for cancer immunotherapy
Yi, M., Li, T., Niu, M., Mei, Q., Zhao, B., Chu, Q., Dai, Z., & Wu, K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01885-w · Cited by 236 · see citing works
Targeting innate immune pathways for cancer immunotherapy
Cao, L. L., & Kagan, J. C. (2023) · Immunity · doi:10.1016/j.immuni.2023.07.018 · Cited by 224 · see citing works
Stem-like exhausted and memory CD8+ T cells in cancer
Gebhardt, T., Park, S. L., & Parish, I. A. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00615-0 · Cited by 216 · see citing works
Designing Cancer Immunotherapies That Engage T Cells and NK Cells
Kyrysyuk, O., & Wucherpfennig, K. W. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101921-044122 · Cited by 215 · see citing works
Meiser, P., Knolle, M. A., Hirschberger, A., de Almeida, G. P., Bayerl, F., Lacher, S. B., Pedde, A., Flommersfeld, S., Hönninger, J., Stark, L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.06.008 · Cited by 202 · see citing works
Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts
Kerdidani, D., Aerakis, E., Verrou, K., Angelidis, I., Douka, K., Maniou, M.-A., Stamoulis, P., Goudevenou, K., Prados, A., Tzaferis, C., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210815 · Cited by 205 · see citing works
Cohen, M., Giladi, A., Barboy, O., Hamon, P., Li, B., Zada, M., Gurevich‐Shapiro, A., Beccaría, C. G., David, E., Maier, B. B., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00338-5 · Cited by 198 · see citing works
Lactate limits CNS autoimmunity by stabilizing HIF-1α in dendritic cells
Sanmarco, L., Rone, J. M., Polonio, C., Lahore, G. F., Giovannoni, F., Ferrara, K., Gutiérrez-Vázquez, C., Li, N., Sokolovska, A., Plasencia, A., et al. (2023) · Nature · doi:10.1038/s41586-023-06409-6 · Cited by 189 · see citing works
Duraiswamy, J., Turrini, R., Minasyan, A., Barras, D., Crespo, I., Grimm, A. J., Casado, J., Genolet, R., Benedetti, F., Wicky, A. M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.008 · Cited by 191 · see citing works
Multi-stage mechanisms of tumor metastasis and therapeutic strategies
Liu, Z., Chen, J., Ren, Y., Liu, S., Ba, Y., Zuo, A., Luo, P., Cheng, Q., Xu, H., & Han, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01955-5 · Cited by 201 · see citing works
The tumor microenvironment’s role in the response to immune checkpoint blockade
Aliazis, K., Christofides, A., Shah, R., Yeo, Y. Y., Jiang, S., Charest, A., & Boussiotis, V. A. (2025) · Nature Cancer · doi:10.1038/s43018-025-00986-3 · Cited by 203 · see citing works
Dendritic cell maturation in cancer
Moon, C. Y., Belabed, M., Park, M. D., Mattiuz, R., Puleston, D. J., & Mérad, M. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-024-00787-3 · Cited by 186 · see citing works
Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes
Kim, S. I., Cassella, C. R., & Byrne, K. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.629722 · Cited by 169 · see citing works
Zhivaki, D., Borriello, F., Chow, O. A., Doran, B. A., Fleming, I., Theisen, D. J., Pallis, P., Shalek, A. K., Sokol, C. L., Zanoni, I., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108381 · Cited by 164 · see citing works
KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance
Zavitsanou, A., Pillai, R., Yuan, H., Wu, W., Bartnicki, E., Karakousi, T. R., Rajalingam, S., Herrera, A. M., Karatza, A., Rashidfarrokhi, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113295 · Cited by 154 · see citing works
In vivo dendritic cell reprogramming for cancer immunotherapy
Ascic, E., Åkerström, F., Nair, M. S., Rosa, A., Kurochkin, I., Zimmermannová, O., Catena, X., Rotankova, N., Veser, C., Rudnik, M., et al. (2024) · Science · doi:10.1126/science.adn9083 · Cited by 148 · see citing works
Challenges in neoantigen-directed therapeutics
Lybaert, L., Lefever, S., Fant, B., Smits, E., Geest, B. G. D., Breckpot, K., Dirix, L. Y., Feldman, S. A., Criekinge, W. V., Thielemans, K., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.013 · Cited by 146 · see citing works
Control of adaptive immunity by pattern recognition receptors
Carroll, S. L., Pasare, C., & Barton, G. M. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.014 · Cited by 146 · see citing works
A vaccine targeting resistant tumours by dual T cell plus NK cell attack
Badrinath, S., Dellacherie, M. O., Li, A. W., Zheng, S., Zhang, X., Sobral, M. C., Pyrdol, J. W., Smith, K. L., Lu, Y., Haag, S., et al. (2022) · Nature · doi:10.1038/s41586-022-04772-4 · Cited by 143 · see citing works
STING licensing of type I dendritic cells potentiates antitumor immunity
Wang, J., Li, S., Wang, M., Wang, X., Chen, S., Sun, Z., Ren, X., Huang, G., Sumer, B. D., Yan, N., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adj3945 · Cited by 142 · see citing works
Zhang, Y., Chen, H., Mo, H., Zhao, N., Sun, X., Liu, B., Gao, R., Xu, B., Zhang, Z., Liu, Z., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.01.007 · Cited by 145 · see citing works
Radiation therapy-induced remodeling of the tumor immune microenvironment
Charpentier, M., Spada, S., Nest, S. J. V., & Demaria, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.003 · Cited by 142 · see citing works
Oba, T., Long, M. D., Keler, T., Marsh, H. C., Minderman, H., Abrams, S. I., Liu, S., & Ito, F. (2020) · Nature Communications · doi:10.1038/s41467-020-19192-z · Cited by 137 · see citing works
The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy
Cueto, F. J., & Sancho, D. (2021) · Cancers · doi:10.3390/cancers13071525 · Cited by 137 · see citing works
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy
Wang, Y., Johnson, K. C. C., Gatti-Mays, M. E., & Li, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01335-y · Cited by 135 · see citing works
CD4+ T cells in antitumor immunity
Montauti, E. I., Oh, D. Y., & Fong, L. H. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.07.009 · Cited by 140 · see citing works
Cross-priming in cancer immunology and immunotherapy
Luri‐Rey, C., Teijeira, Á., Wculek, S. K., de Andrea, C. E., Herrero, C., López‐Janeiro, Á., Rodriguez-Ruiz, M. E., Heras‐Murillo, I., Aggelakopoulou, M., Berraondo, P., et al. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-024-00785-5 · Cited by 143 · see citing works
NF-κB–dependent IRF1 activation programs cDC1 dendritic cells to drive antitumor immunity
Ghislat, G., Cheema, A. S., Baudoin, E., Verthuy, C., Ballester, P. J., Crozat, K., Attaf, N., Dong, C., Milpied, P. J., MALISSEN, B., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abg3570 · Cited by 129 · see citing works
Demystifying the cGAS-STING pathway: precision regulation in the tumor immune microenvironment
Wang, Q., Yu, Y., Zhuang, J., Liu, R., & Sun, C. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02380-0 · Cited by 141 · see citing works
The tumor-draining lymph node as a reservoir for systemic immune surveillance
Delclaux, I., Ventre, K. S., Jones, D., & Lund, A. W. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.09.006 · Cited by 129 · see citing works
Gargaro, M., Scalisi, G., Manni, G., Briseño, C. G., Bagadia, P., Durai, V., Theisen, D. J., Kim, S. K., Castelli, M., Xu, C. A., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.013 · Cited by 126 · see citing works
Kilian, M., Sheinin, R., Tan, C. L., Friedrich, M., Krämer, C., Kaminitz, A., Sanghvi, K., Lindner, K. A. M., Chih, Y., Cichon, F., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.12.007 · Cited by 118 · see citing works
CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses
He, M., Roussak, K., Ma, F., Borcherding, N. C., Garin, V., White, J. M., Schutt, C. R., Jensen, T. I., Zhao, Y., Iberg, C. A., et al. (2023) · Science · doi:10.1126/science.abg2752 · Cited by 120 · see citing works
Wang, Y., Zhong, X., He, X., Hu, Z., Huang, H., Chen, J., Chen, K., Zhao, S., Wei, P., & Li, D. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02729-7 · Cited by 119 · see citing works
Dähling, S., Mansilla, A. M., Knöpper, K., Grafen, A., Utzschneider, D. T., Ugur, M., Whitney, P. G., Bachem, A., Arampatzi, P., Imdahl, F., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.03.006 · Cited by 109 · see citing works
CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies
Bullock, T. N. J. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00734-4 · Cited by 110 · see citing works
cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors
Li, G., Zhao, X., Zheng, Z., Zhang, H., Wu, Y., Shen, Y., & Chen, Q. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05191-6 · Cited by 108 · see citing works
Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy
Sultan, H., Takeuchi, Y., Ward, J. P., Sharma, N., Liu, T., Sukhov, V., Firulyova, M. M., Song, Y., Ameh, S., Brioschi, S., et al. (2024) · Nature · doi:10.1038/s41586-024-07752-y · Cited by 106 · see citing works
Liu, W., Hu, H., Shao, Z., Lv, X., Zhang, Z., Deng, X., Song, Q., Han, Y. N., Guo, T., Xiong, L., et al. (2023) · Bone Research · doi:10.1038/s41413-022-00237-6 · Cited by 101 · see citing works
Decoding immunogenic cell death from a dendritic cell perspective
Janssens, S., Rennen, S., & Agostinis, P. (2023) · Immunological Reviews · doi:10.1111/imr.13301 · Cited by 101 · see citing works
CD4+ helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment
Lei, X., Khatri, I., de Wit, T., de Rink, I., Nieuwland, M., Kerkhoven, R. M., van Eenennaam, H., Sun, C., Garg, A. D., Borst, J. G., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35615-5 · Cited by 95 · see citing works
Type I IFN activating type I dendritic cells for antitumor immunity
Liang, Y., Hannan, R., & Fu, Y.-X. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2564 · Cited by 91 · see citing works
Xia, Y., Sandor, K. D., Pai, J. A., Dániel, B., Raju, S., Wu, R., Hsiung, S., Qi, Y., Tenzin, Y., Okamoto, M., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.003 · Cited by 91 · see citing works
pDC-like cells are pre-DC2 and require KLF4 to control homeostatic CD4 T cells
Rodrigues, P. F., Kouklas, A., Cvijetic, G., Bouladoux, N. J., Mitrovic, M., Desai, J. V., Lima-Junior, D. S., Lionakis, M. S., Belkaid, Y., Ivánek, R., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.add4132 · Cited by 91 · see citing works
The Role of Plasmacytoid Dendritic Cells in Cancers
Zhou, B., Lawrence, T., & Liang, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.749190 · Cited by 90 · see citing works
Glioblastoma vaccines: past, present, and opportunities
Xiong, Z., Raphael, I., Olin, M. R., Okada, H., Li, X., & Kohanbash, G. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2023.104963 · Cited by 90 · see citing works
Zhang, X., Goedegebuure, S. P., Chen, M. Y., Mishra, R., Zhang, F., Yu, Y. Y., Singhal, K., Li, L., Gao, F., Myers, N. B., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01388-3 · Cited by 89 · see citing works
Dendritic cell functions in the inductive and effector sites of intestinal immunity
Luciani, C., Hager, F. T., Cerovic, V., & Lelouard, H. (2021) · Mucosal Immunology · doi:10.1038/s41385-021-00448-w · Cited by 87 · see citing works
Striking a balance: new perspectives on homeostatic dendritic cell maturation
Bosteels, V., & Janssens, S. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01079-5 · Cited by 81 · see citing works
Architects of immunity: How dendritic cells shape CD8 + T cell fate in cancer
Bhandarkar, V., Dinter, T., & Spranger, S. (2025) · Science Immunology · doi:10.1126/sciimmunol.adf4726 · Cited by 83 · see citing works
Garris, C., Wong, J. L., Ravetch, J. V., & Knorr, D. A. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1346 · Cited by 80 · see citing works
Hyperglycosylation of prosaposin in tumor dendritic cells drives immune escape
Sharma, P., Zhang, X., Ly, K., Kim, J. H., Wan, Q., Kim, J., Lou, M., Kain, L., Teyton, L., & Winau, F. (2024) · Science · doi:10.1126/science.adg1955 · Cited by 80 · see citing works
Sittplangkoon, C., Alameh, M.-G., Weissman, D., Lin, P. J. C., Tam, Y. K., Prompetchara, E., & Palaga, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.983000 · Cited by 79 · see citing works
“CD40 signaling in cDC1 is required for tumor rejection by playing a key role in augmenting the proliferation of antigen-specific CD8 T cells (36).”
BackgroundAntigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapy
Moussion, C., & Delamarre, L. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101848 · Cited by 80 · see citing works
Brightman, S. E., Becker, A., Thota, R. R., Naradikian, M. S., Chihab, L. Y., Zavala, K. S., Premlal, A. L. R., Griswold, R. Q., Dolina, J. S., Cohen, E. E. W., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01543-9 · Cited by 77 · see citing works
Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy
Salomon, R., & Dahan, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940674 · Cited by 76 · see citing works
Mechanisms of CD40-dependent cDC1 licensing beyond costimulation
Wu, R., Ohara, R. A., Jo, S., Liu, T., Ferris, S. T., Ou, F., Kim, S. K., Theisen, D. J., Anderson, D. A., Wong, B. W., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01324-w · Cited by 75 · see citing works
Lipid metabolism in dendritic cell biology
You, Z., & Chi, H. (2023) · Immunological Reviews · doi:10.1111/imr.13215 · Cited by 75 · see citing works
CD4 + T cell immunity against cutaneous melanoma encompasses multifaceted MHC II–dependent responses
Bawden, E., Wagner, T., Schröder, J., Effern, M., Hinze, D., Newland, L., Attrill, G. H., Lee, A. R., Engel, S., Freestone, D., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adi9517 · Cited by 75 · see citing works
Humblin, É., Korpas, I., Lu, J., Filipescu, D., van der Heide, V., Goldstein, S., Vaidya, A. B., Schanoski, A. S., Casati, B., Selvan, M. E., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adg0878 · Cited by 74 · see citing works
Lymphatic vessels in the age of cancer immunotherapy
Karakousi, T. R., Mudianto, T., & Lund, A. W. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00681-y · Cited by 78 · see citing works
Zhang, B., Liu, J., Mo, Y., Zhang, K., Huang, B., & Shang, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1476904 · Cited by 76 · see citing works
An Il12 mRNA-LNP adjuvant enhances mRNA vaccine–induced CD8 T cell responses
Aunins, E., Phan, A. T., Alameh, M., Dwivedi, G., Cruz-Morales, E., Christian, D. A., Tam, Y. K., Bunkofske, M. E., Zabala-Peñafiel, A., O’Dea, K. M., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.ads1328 · Cited by 74 · see citing works
Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design
Clemente, B., Denis, M., Silveira, C. P., Schiavetti, F., Brazzoli, M., & Stranges, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1294929 · Cited by 67 · see citing works
Ishihara, M., Kitano, S., Kageyama, S., Miyahara, Y., Yamamoto, N., Kato, H., Mishima, H., Hattori, H., Funakoshi, T., Kojima, T., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003811 · Cited by 69 · see citing works
Dolina, J. S., Lee, J., Brightman, S. E., McArdle, S., Hall, S. M., Thota, R. R., Zavala, K. S., Lanka, M., Premlal, A. L. R., Greenbaum, J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164258 · Cited by 68 · see citing works
DCision-making in tumors governs T cell anti-tumor immunity
Alfei, F., Ho, P., & Lo, W. (2021) · Oncogene · doi:10.1038/s41388-021-01946-8 · Cited by 67 · see citing works
Lei, X., de Groot, D., Welters, M. J. P., de Wit, T., Schrama, E., van Eenennaam, H., Santegoets, S. J. A. M., Oosenbrug, T., van der Veen, A. G., Vos, J. L., et al. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01133-1 · Cited by 68 · see citing works
The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets
Kim, C. W., Kim, K., & Lee, H. K. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.1.224 · Cited by 64 · see citing works
Topchyan, P., Lin, S., & Cui, W. (2023) · Immune Network · doi:10.4110/in.2023.23.e41 · Cited by 68 · see citing works
Dendritic Cells in Shaping Anti-Tumor T Cell Response
Mazzoccoli, L., & Liu, B. (2024) · Cancers · doi:10.3390/cancers16122211 · Cited by 68 · see citing works
Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer
Mahadevan, K. K., Dyevoich, A. M., Chen, Y., Li, B., Sugimoto, H., Sockwell, A. M., McAndrews, K. M., Sthanam, L. K., Wang, H., Shalapour, S., et al. (2024) · Science · doi:10.1126/science.adh4567 · Cited by 68 · see citing works
Type 2 dendritic cells mediate control of cytotoxic T cell resistant tumors
Iwanowycz, S., Ngoi, S. M., Li, Y., Hill, M., Koivisto, C. S., Parrish, M., Guo, B., Li, Z., & Liu, B. (2021) · JCI Insight · doi:10.1172/jci.insight.145885 · Cited by 64 · see citing works
Lança, T., Ungerbäck, J., Silva, C. D., Joeris, T., Ahmadi, F., Vandamme, J., Svensson, M., Mowat, A. M., Kotarsky, K., Sigvardsson, M., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.06.006 · Cited by 64 · see citing works
Kraja, F., Jurišić, V., Hromić-Jahjefendić, A., Rossopoulou, N., Κάτσιλα, Θ., Martinović, K. M., Rivas, J. D. L., Diaconu, C. C., & Szöőr, Á. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1601773 · Cited by 65 · see citing works
Defining and using immune archetypes to classify and treat cancer
Combes, A. J., Samad, B., & Krummel, M. F. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00578-2 · Cited by 59 · see citing works
cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1
Ferris, S. T., Ohara, R. A., Ou, F., Wu, R., Huang, X., Kim, S. K., Chen, J., Liu, T., Schreiber, R. D., Murphy, T. L., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0865 · Cited by 60 · see citing works
Backlund, C. M., Holden, R. L., Moynihan, K. D., Garafola, D., Farquhar, C. E., Mehta, N. K., Maiorino, L., Pham, S., Iorgulescu, J. B., Reardon, D. A., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204078119 · Cited by 60 · see citing works
Antigen-presenting cells as specialized drivers of intestinal T cell functions
Kedmi, R., & Littman, D. R. (2024) · Immunity · doi:10.1016/j.immuni.2024.09.011 · Cited by 60 · see citing works
- Authors
- Ferris, S. T., Durai, V., Wu, R., Theisen, D. J., Ward, J. P., Bern, M. D., Davidson, J. T., Bagadia, P., Liu, T., Briseño, C. G., Li, L., Gillanders, W. E., Wu, G. F., Yokoyama, W. M., Murphy, T. L., Schreiber, R. D., & Murphy, K. M.
- Affiliations
- Washington University in St. Louis (US)
- University of California, San Francisco (US)
- Barnes-Jewish Hospital (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Murphy, Kenneth M.
- ORCID
- Venue
- Nature
- Published
- 2020-08-12
- Volume
- 584
- Issue
- 7822
- Pages
- 624-629
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC7469755
- OpenAlex
- W3048641542
- Cited by
- 611
- References
- 50
- Citations by year
- 2026: 112 · 2025: 105 · 2024: 112 · 2023: 127 · 2022: 76 · 2021: 67 · 2020: 12
- FWCI
- 24.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (UL1TR000448, UL1TR002345)
- National Cancer Institute (T32CA009573, R01CA190700, T32CA009621, R01CA248919, P30CA091842)
- National Institute of Allergy and Infectious Diseases (R01AI150297, R01AI129545, T32AI007163, R01AI162643)
- National Institute of Diabetes and Digestive and Kidney Diseases (F30DK108498, F30DK112466)
- National Institute of Neurological Disorders and Stroke (R01NS106289)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30AR073752)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- conventional type 1 dendritic cells, cDC1, CD4+ T cell priming, CD8+ T cell priming, MHC class II, MHC class I, cross-presentation, tumor rejection, antitumor immunity
- MeSH terms
- Animals, Histocompatibility Antigens Class II, Dendritic Cells, Female, Neoplasms, Signal Transduction, CD4-Positive T-Lymphocytes, Antigen Presentation, CD8-Positive T-Lymphocytes, CD40 Antigens, Cross-Priming, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
